Arlinghaus RB - Search Results

1

Alternative splicing disrupts a nuclear localization signal in spleen tyrosine kinase that is required for invasion suppression in breast cancer.

Wang L, Duke L, Zhang PS, Arlinghaus RB, Symmans WF, Sahin A, Mendez R, Dai JL. Wang L, et al. Among authors: arlinghaus rb. Cancer Res. 2003 Aug 1;63(15):4724-30. Cancer Res. 2003. PMID: 12907655

2

Inhibition of lipocalin 2 impairs breast tumorigenesis and metastasis.

Leng X, Ding T, Lin H, Wang Y, Hu L, Hu J, Feig B, Zhang W, Pusztai L, Symmans WF, Wu Y, Arlinghaus RB. Leng X, et al. Among authors: arlinghaus rb. Cancer Res. 2009 Nov 15;69(22):8579-84. doi: 10.1158/0008-5472.CAN-09-1934. Epub 2009 Nov 3. Cancer Res. 2009. PMID: 19887608

3

Bcr and Abl interaction: oncogenic activation of c-Abl by sequestering Bcr.

Ling X, Ma G, Sun T, Liu J, Arlinghaus RB. Ling X, et al. Among authors: arlinghaus rb. Cancer Res. 2003 Jan 15;63(2):298-303. Cancer Res. 2003. PMID: 12543778

4

Knockdown of STAT3 expression by RNA interference inhibits the induction of breast tumors in immunocompetent mice.

Ling X, Arlinghaus RB. Ling X, et al. Among authors: arlinghaus rb. Cancer Res. 2005 Apr 1;65(7):2532-6. doi: 10.1158/0008-5472.CAN-04-2425. Cancer Res. 2005. PMID: 15805244

5

Janus kinase 2: a critical target in chronic myelogenous leukemia.

Samanta AK, Lin H, Sun T, Kantarjian H, Arlinghaus RB. Samanta AK, et al. Among authors: arlinghaus rb. Cancer Res. 2006 Jul 1;66(13):6468-72. doi: 10.1158/0008-5472.CAN-06-0025. Cancer Res. 2006. PMID: 16818614

6

Expression of a truncated first exon BCR sequence in chronic myelogenous leukemia cells blocks cell growth and induces cell death.

Wang Y, Liu J, Wu Y, Luo W, Lin SH, Lin H, Hawk N, Sun T, Guo JQ, Estrov Z, Talpaz M, Champlin R, Arlinghaus RB. Wang Y, et al. Among authors: arlinghaus rb. Cancer Res. 2001 Jan 1;61(1):138-44. Cancer Res. 2001. PMID: 11196151

7

Sequences within the first exon of BCR inhibit the activated tyrosine kinases of c-Abl and the Bcr-Abl oncoprotein.

Liu J, Wu Y, Arlinghaus RB. Liu J, et al. Among authors: arlinghaus rb. Cancer Res. 1996 Nov 15;56(22):5120-4. Cancer Res. 1996. PMID: 8912843

8

Inhibition of the Bcr-Abl oncoprotein by Bcr requires phosphoserine 354.

Hawk N, Sun T, Xie S, Wang Y, Wu Y, Liu J, Arlinghaus RB. Hawk N, et al. Among authors: arlinghaus rb. Cancer Res. 2002 Jan 15;62(2):386-90. Cancer Res. 2002. PMID: 11809685

9

Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia.

Donato NJ, Wu JY, Stapley J, Lin H, Arlinghaus R, Aggarwal BB, Shishodia S, Albitar M, Hayes K, Kantarjian H, Talpaz M. Donato NJ, et al. Cancer Res. 2004 Jan 15;64(2):672-7. doi: 10.1158/0008-5472.can-03-1484. Cancer Res. 2004. PMID: 14744784

10

P210 Bcr-Abl interacts with the interleukin 3 receptor beta(c) subunit and constitutively induces its tyrosine phosphorylation.

Wilson-Rawls J, Xie S, Liu J, Laneuville P, Arlinghaus RB. Wilson-Rawls J, et al. Among authors: arlinghaus rb. Cancer Res. 1996 Aug 1;56(15):3426-30. Cancer Res. 1996. PMID: 8758906

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

263 results

Search Page

Filters